<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31562223</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study.</ArticleTitle><Pagination><StartPage>604</StartPage><EndPage>607</EndPage><MedlinePgn>604-607</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.119.231985</ELocationID><Abstract><AbstractText>Neuroinflammation is important in amyotrophic lateral sclerosis (ALS). The P2X7 receptor (P2X7R) is a promising target for neuroinflammation. The objective of this study was to compare <sup>18</sup>F-DPA714, a second-generation translocator protein tracer, with <sup>11</sup>C-JNJ717, a novel P2X7R tracer, in vitro and in vivo in ALS. <b>Methods:</b> For the in vitro portion of the study, autoradiography with <sup>18</sup>F-DPA714 and <sup>11</sup>C-JNJ717 was performed on human ALS brain sections in comparison to immunofluorescence with Iba1 and GFAP. For the in vivo portion, 3 male patients with early-stage ALS (59.3 &#xb1; 7.2 y old) and 6 healthy volunteers (48.2 &#xb1; 16.5 y old, 2 men and 4 women) underwent dynamic PET/MR scanning with <sup>18</sup>F-DPA714 and <sup>11</sup>C-JNJ717. Volume-of-distribution images were calculated using Logan plots and analyzed on a volume-of-interest basis. <b>Results:</b> Autoradiography showed no difference in <sup>11</sup>C-JNJ717 binding but did show increased <sup>18</sup>F-DPA714 binding in the motor cortex correlating with Iba1 expression (glial cells). Similar findings were observed in vivo, with a 13% increase in <sup>18</sup>F-DPA714 binding in the motor cortex. <b>Conclusion:</b> In symptomatic ALS patients, <sup>18</sup>F-DPA714 showed increased signal whereas <sup>11</sup>C-JNJ717 was not elevated.</AbstractText><CopyrightInformation>&#xa9; 2020 by the Society of Nuclear Medicine and Molecular Imaging.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium donatienne.vanweehaeghe@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Schoor</LastName><ForeName>Evelien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, and Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vocht</LastName><ForeName>Joke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, and Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koole</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attili</LastName><ForeName>Bala</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celen</LastName><ForeName>Sofie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Declercq</LastName><ForeName>Lieven</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, UZ Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, and Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bormans</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C530129">N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058486">Receptors, Purinergic P2X7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499229">TSPO protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>GZ5I74KB8G</RegistryNumber><NameOfSubstance UI="C000615276">Fluorine-18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058486" MajorTopicYN="N">Receptors, Purinergic P2X7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">P2X7</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">brain specimen</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">translocator protein (TSPO)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31562223</ArticleId><ArticleId IdType="pmc">PMC7198372</ArticleId><ArticleId IdType="doi">10.2967/jnumed.119.231985</ArticleId><ArticleId IdType="pii">jnumed.119.231985</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boill&#xe9;e S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargsyan SA, Monk PN, Shaw PJ. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia. 2005;51:241&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15846792</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher NR, Loggia ML, Lawson R, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. Neuroimage Clin. 2015;7:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami C, Iaccarino L, Perani D. Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging. Int J Mol Sci. 2017;18:E933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5454906</ArticleId><ArticleId IdType="pubmed">28475165</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Howell OW, Tang SP, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30:1608&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949260</ArticleId><ArticleId IdType="pubmed">20424634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ory D, Celen S, Gijsbers R, et al. Preclinical evaluation of a P2X7 receptor-selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in nonhuman primates. J Nucl Med. 2016;57:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">27199364</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Koole M, Schmidt M, et al. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson&#x2019;s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2019;46:2051&#x2013;2064.</Citation><ArticleIdList><ArticleId IdType="pubmed">31243495</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lak M, Roszek K, Wujak M. Purinergic implication in amyotrophic lateral sclerosis: from pathological mechanisms to therapeutic perspectives. Purinergic Signal. 2019;15:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J Neuroinflammation. 2015;12:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451729</ArticleId><ArticleId IdType="pubmed">26022249</ArticleId></ArticleIdList></Reference><Reference><Citation>Monif M, Burnstock G, Williams DA. Microglia: proliferation and activation driven by the P2X7 receptor. Int J Biochem Cell Biol. 2010;42:1753&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavisse S, Inoue K, Jan C, et al. [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. Eur J Nucl Med Mol Imaging. 2015;42:478&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">25488184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ory D, Postnov A, Koole M, et al. Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET. Eur J Nucl Med Mol Imaging. 2016;43:163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">26323575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ory D, Planas A, Dresselaers T, et al. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nucl Med Biol. 2015;42:753&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">26220690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>